MG
PCVX icon

Michael Gelband’s Vaxcyte PCVX Stock Holding History

Michael Gelband’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Sell
42,357
-83,470
-66% -$4.53M 0.02% 748
2026
Q1 		$7.31M Buy
+125,827
New +$6.83M 0.06% 317
2021
Q4 		– Sell
-14,300
Closed -$363K – 2494
2021
Q3 		$363K Buy
+14,300
New +$347K ﹤0.01% 1539

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Michael Gelband's PCVX Position: Q2 2026 in Review

Michael Gelband reduced its Vaxcyte (PCVX) stake by 66% in Q2 2026, selling an estimated $4.53M and leaving 42,357 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #748.

Michael Gelband first reported a position in PCVX in Q3 2021 and has held it in 3 quarters since. The position peaked at $7.31M in Q1 2026. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Michael Gelband held 42,357 shares of Vaxcyte worth $2.46M as of Q2 2026.
  • Michael Gelband sold 83,470 Vaxcyte shares in Q2 2026, an estimated $4.53M.
  • Vaxcyte made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #748 holding.
  • Michael Gelband first reported a position in Vaxcyte in Q3 2021 and has held it in 3 quarters since.
  • Michael Gelband's Vaxcyte position peaked at $7.31M in Q1 2026.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.